From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
NSC 357754 dihydrochloride is an inhibitor of Claudin. NSC 357754 dihydrochloride can increase the transepithelial electrical resistance of cells and reduce the permeability of specific cations. NSC 357754 dihydrochloride can be used in the research of intestinal diseases mediated by Claudin-2 and/or Claudin-15 .
PDS-0330 is a specific and potent Claudin-1 inhibitor. PDS-0330 interferes with claudin-1/Src association and inhibits colorectal cancer (CRC) progression and metastasis .
RTSPSSR is synthesized peptide, which binds specifically to claudin-1 and visulizes the CRC tumor in mice, through near-infrared fluorescence imaging .
9,10-Phenanthrenequinone is an inhibitor of claudin-5/CLDN5 that induces apoptosis via a NO synthase/ROS-dependent mechanism. 9,10-Phenanthrenequinone also promotes endothelial barrier dysfunction by promoting caspase activation and DNA fragmentation, and reducing CLDN5 expression and proteasomal proteolysis .
Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
NSC 357754 is an inhibitor of Claudin. NSC 357754 can increase the transepithelial electrical resistance of cells and reduce the permeability of specific cations. NSC 357754 can be used in the research of intestinal diseases mediated by Claudin-2 and/or Claudin-15 .
Lauroylcarnitine chloride enhances the absorption of salmon calcitonin in rats. Also in determining in situ bioavailability, increased availability of Lucifer yellow and decreased expression of claudin-4 protein in the colon .
Garetatug is a humanized monoclonal antibody targeting human CLDN18 (claudin-18). Garetatug specifically binds to CLDN18, interfering with relevant cell signaling pathways and exerting antitumor activity .
Ixotatug is a monoclonal antibody targeting human CLDN6 (claudin-6). Ixotatug specifically binds to CLDN6, interfering with relevant signaling pathways in tumor cells and exerting antitumor activity. Ixotatug is promising for research of cancers .
OM-7D3-B3 is a monoclonal antibody targeting human claudin-1 (CLDN1) (Kd = 4 nM). OM-7D3-B3 blocks the process in which CLDN1 is involved in the entry of hepatitis C virus (HCV) into cells. OM-7D3-B3 is promising for research of HCV infection .
Elatatug is an anti-CLDN18 (claudin 18) IgG1κ type humanized antibody with antineoplastic activity. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
IMAB027 (ASP1650) is a specific anti-CLDN6 mAb, while CLDN6(Claudin 6) is a tight junction membrane protein, aberrantly expressed in various human cancer types, ovarian cancers particularly. IMAB 027 shows anti-tumor activity, and induces apoptosis in CLDN6 + ovarian and testicular cancer cell lines .
Osemitamab (FUT8-KO) is an anti-claudin-18.2 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
PIK3CG Recombinant Human Active Lipid Kinase belongs to PI3K enzyme family that is directly regulated by Gβγ and Ras in the G protein coupled receptor (GPCR) pathway. PIK3CG has the function of regulating cellular inflammation and immunity. PIK3CG is also a potential target for the treatment of a few malignant tumors such as acute lymphoblastic leukemia, medulloblastoma, claudin-low breast cancer (CLBC) and Kaposi sarcoma .
Xylobiose (1,4-β-D-Xylobiose; 1,4-D-Xylobiose) is an orally active Claudin 2/CLDN2 inhibitor and HSP27 inducer. Xylobiose works by regulating intestinal barrier function and glucose and lipid metabolism-related signaling pathways. Xylobiose inhibits CLDN2 expression to reduce intestinal permeability, induces HSP27 to enhance cell protection, and regulates the miR-122a/miR-33a axis to inhibit liver lipid synthesis and improve insulin resistance. Xylobiose can strengthen intestinal barrier integrity, reduce blood sugar and blood lipid levels, and reduce oxidative stress and inflammatory response. Xylobiose can be used in the study of type 2 diabetes and metabolic syndrome .
Xylobiose (1,4-β-D-Xylobiose; 1,4-D-Xylobiose) is an orally active Claudin 2/CLDN2 inhibitor and HSP27 inducer. Xylobiose works by regulating intestinal barrier function and glucose and lipid metabolism-related signaling pathways. Xylobiose inhibits CLDN2 expression to reduce intestinal permeability, induces HSP27 to enhance cell protection, and regulates the miR-122a/miR-33a axis to inhibit liver lipid synthesis and improve insulin resistance. Xylobiose can strengthen intestinal barrier integrity, reduce blood sugar and blood lipid levels, and reduce oxidative stress and inflammatory response. Xylobiose can be used in the study of type 2 diabetes and metabolic syndrome .
RTSPSSR is synthesized peptide, which binds specifically to claudin-1 and visulizes the CRC tumor in mice, through near-infrared fluorescence imaging .
Zolbetuximab (IMAB362) is a monoclonal antibody targeting Claudin-18.2. Zolbetuximab mediates specific killing of Claudin-18.2-positive cells through immune effector mechanisms. Zolbetuximab can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors .
Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
IMAB027 (ASP1650) is a specific anti-CLDN6 mAb, while CLDN6(Claudin 6) is a tight junction membrane protein, aberrantly expressed in various human cancer types, ovarian cancers particularly. IMAB 027 shows anti-tumor activity, and induces apoptosis in CLDN6 + ovarian and testicular cancer cell lines .
Garetatug is a humanized monoclonal antibody targeting human CLDN18 (claudin-18). Garetatug specifically binds to CLDN18, interfering with relevant cell signaling pathways and exerting antitumor activity .
Ixotatug is a monoclonal antibody targeting human CLDN6 (claudin-6). Ixotatug specifically binds to CLDN6, interfering with relevant signaling pathways in tumor cells and exerting antitumor activity. Ixotatug is promising for research of cancers .
OM-7D3-B3 is a monoclonal antibody targeting human claudin-1 (CLDN1) (Kd = 4 nM). OM-7D3-B3 blocks the process in which CLDN1 is involved in the entry of hepatitis C virus (HCV) into cells. OM-7D3-B3 is promising for research of HCV infection .
Elatatug is an anti-CLDN18 (claudin 18) IgG1κ type humanized antibody with antineoplastic activity. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
Osemitamab (FUT8-KO) is an anti-claudin-18.2 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
Xylobiose (1,4-β-D-Xylobiose; 1,4-D-Xylobiose) is an orally active Claudin 2/CLDN2 inhibitor and HSP27 inducer. Xylobiose works by regulating intestinal barrier function and glucose and lipid metabolism-related signaling pathways. Xylobiose inhibits CLDN2 expression to reduce intestinal permeability, induces HSP27 to enhance cell protection, and regulates the miR-122a/miR-33a axis to inhibit liver lipid synthesis and improve insulin resistance. Xylobiose can strengthen intestinal barrier integrity, reduce blood sugar and blood lipid levels, and reduce oxidative stress and inflammatory response. Xylobiose can be used in the study of type 2 diabetes and metabolic syndrome .
Xylobiose (1,4-β-D-Xylobiose; 1,4-D-Xylobiose) is an orally active Claudin 2/CLDN2 inhibitor and HSP27 inducer. Xylobiose works by regulating intestinal barrier function and glucose and lipid metabolism-related signaling pathways. Xylobiose inhibits CLDN2 expression to reduce intestinal permeability, induces HSP27 to enhance cell protection, and regulates the miR-122a/miR-33a axis to inhibit liver lipid synthesis and improve insulin resistance. Xylobiose can strengthen intestinal barrier integrity, reduce blood sugar and blood lipid levels, and reduce oxidative stress and inflammatory response. Xylobiose can be used in the study of type 2 diabetes and metabolic syndrome .
Claudin-6/CLDN6 Protein-VLP, Cynomolgus (HEK293) is recommended for SPR analysis, animal immunization, ELISA, PK assay. If VLP control is required, it is recommended HY-P702775. May have binding signals with Anti-His antibodies.
Claudin-6/CLDN6 Protein-VLP, Mouse (HEK293) is recommended for animal immunization, ELISA, PK assay. If VLP control is required, it is recommended HY-P702775. May have binding signals with Anti-His antibodies.
Claudin-6/CLDN6 Protein-VLP, Human (HEK293) is recommended for SPR analysis, animal immunization, ELISA, PK assay. May have binding signals with Anti-His antibodies.
CLDN18 play a crucial role in alveolar fluid homeostasis by modulating tight junction composition, affecting ion transport and solute permeability. They contribute to alveolarization and the paracellular epithelial barrier, affecting epithelial progenitor cell proliferation and organ size by controlling YAP1 subcellular localization. Claudin-18/CLDN18.2 Protein, Human (His) is the recombinant human-derived Claudin-18/CLDN18.2 protein, expressed by E. coli , with N-8*His labeled tag. The complete sequence length is 172 amino acids. In addition to the target fragment P56856-2 (D28-L76), there are other fusion sequences that play a role in stabilizing the extracellular region.
Claudin-9/CLDN9 Protein-VLP, Human (HEK293, His) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P701236. Tags can only be detected under denaturing conditions.
Claudin-6/CLDN6 Protein-VLP, Human (HEK293) is recommended for SPR analysis, animal immunization, ELISA, PK assay. If VLP control is required, it is recommended HY-P702775. May have binding signals with Anti-His antibodies.
Claudin-6/CLDN6 Protein-VLP is pivotal in targeted elimination of intercellular spaces within tight junctions, ensuring cell barrier integrity and polarity. Moreover, it serves as a receptor for hepatitis C virus (HCV), facilitating viral entry into hepatic cells. Claudin-6 Protein-Nanodisc, Human (HEK293, GFP, His) is the recombinant human-derived Claudin-6 protein, expressed by HEK293, with C-His and C-GFP labeled tag.
Claudin-6/CLDN6 Protein-VLP, Human (Biotinylated, HEK293) is available in solution form, no concentration information, recommended only for SPR analysis. HY-P77899 can be used in animal immunization, ELISA, PK assay. If VLP control is required, it is recommended HY-P702775. May have binding signals with Anti-His antibodies.
Claudin-6/CLDN6 Protein-VLP, Human (HEK293, His) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P701236. Tags can only be detected under denaturing conditions.
Claudin-6/CLDN6 Protein-VLP, Human (HEK293, GFP) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P701236. Tags can only be detected under denaturing conditions.
Claudin-18/CLDN18.1 Protein-VLP, Human (HEK293, mCherry) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P701236. Tags can only be detected under denaturing conditions.
Claudin-9/CLDN9 protein-VLP plays a crucial role in tight junctions by eliminating intercellular spaces through calcium-independent cell adhesion activity. In microbial infections, it acts as a receptor that facilitates the entry of hepatitis C virus (HCV) into hepatocytes. Claudin-9/CLDN9 Protein-VLP, Human (HEK293) is the recombinant human-derived Claudin-9/CLDN9 protein, expressed by HEK293, with tag free.It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P701236. Tags can only be detected under denaturing conditions.
Claudin-6/CLDN6 Protein-VLP is pivotal in targeted elimination of intercellular spaces within tight junctions, ensuring cell barrier integrity and polarity. Moreover, it serves as a receptor for hepatitis C virus (HCV), facilitating viral entry into hepatic cells. Claudin-6/CLDN6 Protein-VLP, Human (HEK293, GFP, solution) is the recombinant human-derived Claudin-6/CLDN6 protein, expressed by HEK293, with tag free.Formed in HEK293 cultures, these VLPs concentrate membrane proteins on the cell surface, producing high-concentration proteins ideal for immunization and antibody screening. Given the high immunogenicity of VLPs, the immunization protocol such as antigen dose, schedule, and adjuvant, requires optimization. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P705435.
Claudin-6/CLDN6 Protein-VLP is pivotal in targeted elimination of intercellular spaces within tight junctions, ensuring cell barrier integrity and polarity. Moreover, it serves as a receptor for hepatitis C virus (HCV), facilitating viral entry into hepatic cells. Claudin-6/CLDN6 Protein, Human (sf9, His, Twin-Strep, Nanodisc) is the recombinant human-derived Claudin-6/CLDN6 protein, expressed by sf9 insect cells, with C-Twin-Strep and N-His labeled tag.
Claudin-6/CLDN6 Protein-VLP is pivotal in targeted elimination of intercellular spaces within tight junctions, ensuring cell barrier integrity and polarity. Moreover, it serves as a receptor for hepatitis C virus (HCV), facilitating viral entry into hepatic cells. Claudin-6/CLDN6 Protein-Nanodisc, Human (HEK293, His, Flag, GFP) is the recombinant human-derived Claudin-6/CLDN6 protein, expressed by HEK293, with N-His and C-GFP and N-Flag labeled tag.
Claudin-11/CLDN11 Protein plays a crucial role in tightly closing intercellular spaces in tight junctions, facilitated by its calcium-independent cell-adhesion capabilities. Interacting with tetraspanin-3/TSPAN3 suggests potential collaboration in cellular processes. CLDN11's associations with OCLN highlight its involvement in molecular interactions, contributing to the structural integrity and functional regulation of tight junctions. Claudin-11/CLDN11 Protein, Human (HEK293, Fc) is the recombinant human-derived Claudin-11/CLDN11 protein, expressed by HEK293 , with N-mFc labeled tag.
Claudin-9/CLDN9 protein-VLP plays a crucial role in tight junctions by eliminating intercellular spaces through calcium-independent cell adhesion activity. In microbial infections, it acts as a receptor that facilitates the entry of hepatitis C virus (HCV) into hepatocytes. Claudin-9/CLDN9 Protein-Nanodisc, Human (Biotinylated, HEK293, His, Avi) is the recombinant human-derived Claudin-9/CLDN9 protein, expressed by HEK293, with C-His and C-Avi labeled tag.
Claudin-18/CLDN18.2 Protein-VLP, Human (HEK293) is recommended for SPR analysis, animal immunization, ELISA, PK assay. If VLP control is required, it is recommended HY-P702775. May have binding signals with Anti-His antibodies.
CLDN18 play a crucial role in alveolar fluid homeostasis by modulating tight junction composition, affecting ion transport and solute permeability. They contribute to alveolarization and the paracellular epithelial barrier, affecting epithelial progenitor cell proliferation and organ size by controlling YAP1 subcellular localization. Claudin-18/CLDN18.1 Protein, Human (His) is the recombinant human-derived Claudin-18/CLDN18.1 protein, expressed by E. coli , with N-8*His labeled tag. The complete sequence length is 171 amino acids. In addition to the target fragment P56856-1 (D28-L76), there are other fusion sequences that play a role in stabilizing the extracellular region.
Claudin-18/CLDN18.2 Protein-VLP, Human (Biotinylated, HEK293) is available in solution form, no concentration information, recommended only for SPR analysis. HY-P78368 can be used in animal immunization, ELISA, PK assay. If VLP control is required, it is recommended HY-P702775. May have binding signals with Anti-His antibodies.
Claudin-18/CLDN18.2 Protein-VLP, Human (HEK293, His) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P701236. Tags can only be detected under denaturing conditions.
CLDN18-VLPs (Claudin 18 virus-like particles) play a crucial role in alveolar fluid homeostasis by modulating tight junction composition, affecting ion transport and solute permeability. They contribute to alveolarization and the paracellular epithelial barrier, affecting epithelial progenitor cell proliferation and organ size by controlling YAP1 subcellular localization. Claudin-18/CLDN18.2 Protein-VLP, Human (HEK293, GFP) is the recombinant human-derived Claudin-18/CLDN18.2 protein, expressed by HEK293, with GFP labeled tag.Formed in HEK293 cultures, these VLPs concentrate membrane proteins on the cell surface, producing high-concentration proteins ideal for immunization and antibody screening. Given the high immunogenicity of VLPs, the immunization protocol such as antigen dose, schedule, and adjuvant, requires optimization. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P705435.
Claudin-18/CLDN18.2 Protein-VLP, Macaca fascicularis (HEK293, His) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P701236. Tags can only be detected under denaturing conditions.
CLDN18-VLPs (Claudin 18 virus-like particles) play a crucial role in alveolar fluid homeostasis by modulating tight junction composition, affecting ion transport and solute permeability. They contribute to alveolarization and the paracellular epithelial barrier, affecting epithelial progenitor cell proliferation and organ size by controlling YAP1 subcellular localization. Claudin-18/CLDN18.2 Protein, Human (sf9, Twin Strep, Nanodisc) is the recombinant human-derived Claudin-18/CLDN18.2 protein, expressed by sf9 insect cells, with C-Twin-Strep and N-His labeled tag.
Claudin-4/CLDN4 Protein-VLP, Human (HEK293, His) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P701236. Tags can only be detected under denaturing conditions.
Claudin-4/CLDN4 protein-VLP is a channel-forming tight junction protein that promotes paracellular chloride transport in the kidney. It is essential for the reabsorption of filtered chloride in the collecting duct. Claudin-4/CLDN4 Protein-VLP, Human (HEK293) is the recombinant human-derived Claudin-4/CLDN4 protein, expressed by HEK293, with tag free.Formed in HEK293 cultures, these VLPs concentrate membrane proteins on the cell surface, producing high-concentration proteins ideal for immunization and antibody screening. Given the high immunogenicity of VLPs, the immunization protocol such as antigen dose, schedule, and adjuvant, requires optimization. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P705433.
Claudin-4/CLDN4 protein-VLP is a channel-forming tight junction protein that promotes paracellular chloride transport in the kidney. It is essential for the reabsorption of filtered chloride in the collecting duct. Claudin-4/CLDN4 Protein-Nanodisc, Human (HEK293,His, Strep) is the recombinant human-derived Claudin-4/CLDN4 protein, expressed by HEK293, with C-Strep and N-His labeled tag.
Claudin-18/CLDN18.2 Protein-VLP, Mouse (HEK293, His) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P701236. Tags can only be detected under denaturing conditions.
The CLDN1 protein is a tight junction component that regulates epithelial permeability. Claudin-1 Protein-VLP, Human (HEK293) is the recombinant human-derived Claudin-1 protein, expressed by HEK293, with tag free.Formed in HEK293 cultures, these VLPs concentrate membrane proteins on the cell surface, producing high-concentration proteins ideal for immunization and antibody screening. Given the high immunogenicity of VLPs, the immunization protocol such as antigen dose, schedule, and adjuvant, requires optimization. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P705433.
Claudin-3/CLDN3 proteins play a critical role in tight junctions, eliminating intercellular spaces through calcium-independent cell adhesion activity. It exhibits multifunctionality by forming homo- and heteropolymers with other CLDN members, including CLDN1 and CLDN2. Claudin-3/CLDN3 Protein, Human (His-B2M) is the recombinant human-derived Claudin-3/CLDN3 protein, expressed by E. coli , with N-6*His, B2M labeled tag.
Claudin-3/CLDN3 Protein-VLP, Human (HEK293, His) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P701236. Tags can only be detected under denaturing conditions.
Claudin-3/CLDN3 proteins play a critical role in tight junctions, eliminating intercellular spaces through calcium-independent cell adhesion activity. It exhibits multifunctionality by forming homo- and heteropolymers with other CLDN members, including CLDN1 and CLDN2. Claudin-3/CLDN3 Protein-VLP, Human (HEK293) is the recombinant human-derived Claudin-3/CLDN3 protein, expressed by HEK293, with tag free.Formed in HEK293 cultures, these VLPs concentrate membrane proteins on the cell surface, producing high-concentration proteins ideal for immunization and antibody screening. Given the high immunogenicity of VLPs, the immunization protocol such as antigen dose, schedule, and adjuvant, requires optimization. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P705433.
